1. Home
  2. CALC vs NSPR Comparison

CALC vs NSPR Comparison

Compare CALC & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$6.00

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$1.88

Market Cap

81.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CALC
NSPR
Founded
2011
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.3M
81.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CALC
NSPR
Price
$6.00
$1.88
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$16.00
$4.00
AVG Volume (30 Days)
93.6K
58.9K
Earning Date
11-12-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,779,000.00
Revenue This Year
N/A
$22.76
Revenue Next Year
N/A
$75.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.04
52 Week Low
$1.42
$1.59
52 Week High
$7.20
$3.80

Technical Indicators

Market Signals
Indicator
CALC
NSPR
Relative Strength Index (RSI) 66.17 45.56
Support Level $5.75 $1.89
Resistance Level $7.20 $2.17
Average True Range (ATR) 0.59 0.15
MACD 0.10 0.01
Stochastic Oscillator 60.56 39.53

Price Performance

Historical Comparison
CALC
NSPR

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

Share on Social Networks: